It was unclear whether an increased number of common nevi (moles) predicts melanoma death.
We prospectively examined the association between number of common nevi and risk of melanoma death.
Our study used data from the Nurses' Health Study (n = 77,288 women) and Health Professionals Follow-up Study (n = 32,455 men). In 1986, participants were asked about the number of moles they had with a ≥3-mm diameter on the upper extremity, and we stratified their answers into 3 categories (none, 1-2, or ≥3) on the basis of data distribution.
During follow-up (1986-2012), 2452 melanoma cases were pathologically confirmed; among these, we identified 196 deaths due to melanoma. Increased number of nevi was associated with melanoma death; the hazard ratio (HR) for ≥3 nevi compared with no nevi was 2.49 (95% confidence interval [CI] 1.50-4.12) for women and 3.97 (95% CI 2.54-6.22) for men. Among melanoma cases, increased number of nevi was associated with melanoma death in men (≥3 nevi, HR 1.89, 95% CI 1.17-3.05) but not in women. Similarly, the number of nevi was positively associated with Breslow thickness in men only (Ptrend = .01).
This is an epidemiologic study without examination into mechanisms.
Increased number of cutaneous nevi was significantly associated with melanoma death. High nevus count might serve as an independent prognostic factor to predict the risk of melanoma death particularly among male melanoma patients.Le texte complet de cet article est disponible en PDF.
Key words : Breslow thickness, cohort study, common nevi, death, melanoma
Abbreviations used : CI, HPFS, HR, NHS, SD
| Funding sources: Supported by the Research Career Development Award of the Dermatology Foundation and National Institutes of Health grants for the Nurses' Health Study (P01 CA87969 and UM1 CA186107), Nurses' Health Study II (UM1 CA176726), and Health Professionals Follow-up Study (UM1 CA167552).
| Previously presented as a poster at the American Association for Cancer Research 2017 meeting in Washington, DC, April 1-5, 2017, and the Society for Investigative Dermatology 2017 meeting in Portland, Oregon, April 26-29, 2017.
| Conflicts of interest: None disclosed.
| Disclaimer: The views presented in this manuscript do not necessarily represent the views of the Department of Veteran Affairs. Funding sources had no role in the study design and conduct; collection, management, analysis, and interpretation of data; preparation, review, or approval of the report; or decision to submit the article for publication.
| Reprints not available from the authors.